Luc Dirix

Luc Dirix

UNVERIFIED PROFILE

Are you Luc Dirix?   Register this Author

Register author
Luc Dirix

Luc Dirix

Publications by authors named "Luc Dirix"

Are you Luc Dirix?   Register this Author

100Publications

4121Reads

5Profile Views

Pathological features of vessel co-option versus sprouting angiogenesis.

Angiogenesis 2019 Oct 26. Epub 2019 Oct 26.

Translational Cancer Research Unit, GZA Hospitals, Sint-Augustinus, Antwerp, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10456-019-09690-0DOI Listing
October 2019

Predictive Significance of Androgen Receptor Splice Variant 7 in Patients With Metastatic Castration-Resistant Prostate Cancer: The PROPHECY Study.

Authors:
Luc Dirix

J Clin Oncol 2019 Aug 2;37(24):2180-2181. Epub 2019 Jul 2.

Luc Dirix, MD, PhD, University of Antwerp and GZA Sint-Augustinus, Antwerp, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.00811DOI Listing
August 2019

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.

JAMA Oncol 2019 Jul;5(7):1060-1062

Department of Medical Epidemiology and Biostatistics, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.0869DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499126PMC
July 2019

AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer.

Future Oncol 2019 Jun 12;15(17):1963-1973. Epub 2019 Apr 12.

Immutep SAS; Parc Club Orsay, Orsay, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0807DOI Listing
June 2019

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nature 2019 02;566(7742):E1

Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41586-019-0883-2
Publisher Site
http://dx.doi.org/10.1038/s41586-019-0883-2DOI Listing
February 2019

An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA.

J Mol Diagn 2019 Jan 6;21(1):123-137. Epub 2018 Oct 6.

Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands; Cancer Genomics Netherlands, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmoldx.2018.08.010DOI Listing
January 2019

Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy.

Semin Cancer Biol 2018 10 31;52(Pt 2):86-93. Epub 2018 Jan 31.

Translational Cancer Research Unit (CORE), Gasthuiszusters Antwerpen Hospitals, University of Antwerp, Wilrijk, Antwerp, Belgium; HistoGeneX NV, Wilrijk, Antwerp, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2018.01.009DOI Listing
October 2018

Adjuvant aromatase inhibition: more options for patients.

Authors:
Luc Y Dirix

Lancet Oncol 2018 04 23;19(4):431-432. Epub 2018 Feb 23.

AZ-Sint-Augustinus, University of Antwerp, Antwerp B-2610, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30155-4DOI Listing
April 2018

Emerging trends in the treatment of advanced basal cell carcinoma.

Cancer Treat Rev 2018 Mar 14;64:1-10. Epub 2017 Dec 14.

Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.12.009DOI Listing
March 2018

Pneumocystis jiroveci pneumonia (PJP) in non-HIV immunocompromised individuals.

Acta Clin Belg 2017 Dec 27;72(6):413-416. Epub 2017 Mar 27.

d Intensive Care Unit, Sint-Augustinus Hospital , Wilrijk , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17843286.2017.1305136DOI Listing
December 2017

Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC).

Neoplasia 2017 Jul 10;19(7):564-573. Epub 2017 Jun 10.

The Laboratory for Cytoskeletal Physiology, Department of Biological Sciences, The University of Delaware, Newark, DE; The Center for Translational Cancer Research, The University of Delaware, Newark, DE; The Helen F. Graham Cancer Center, Newark, DE. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2017.03.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470553PMC
July 2017

Neratinib for the treatment of breast cancer.

Expert Opin Pharmacother 2016 Nov 17;17(16):2243-2248. Epub 2016 Oct 17.

a Breast Unit, Medical Oncology , Sint-Augustinus Cancer Centre, Iridium Network , Antwerp , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2016.1244528DOI Listing
November 2016

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.

Neoplasia 2016 Nov 17;18(11):647-653. Epub 2016 Oct 17.

Erasmus MC Cancer Institute, Erasmus University Medical Center, Department of Medical Oncology and Cancer Genomics Netherlands, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2016.08.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071539PMC
November 2016

LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.

Mol Oncol 2016 10 25;10(8):1363-73. Epub 2016 Jul 25.

Department of Medical Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2016.07.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423197PMC
October 2016

Evaluation and consequences of heterogeneity in the circulating tumor cell compartment.

Oncotarget 2016 07;7(30):48625-48643

Center for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.8015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217044PMC
July 2016

Management of pulmonary toxicity associated with targeted anticancer therapies.

Expert Opin Drug Metab Toxicol 2015 19;11(11):1695-707. Epub 2015 Aug 19.

c 3 Sint-Augustinus, Medical Oncology , Oosterveldlaan 24, 2610 Wilrijk-Antwerp, Belgium +32 34 433 737 ; +32 34 430 09 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425255.2015.1080687DOI Listing
June 2016

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nature 2016 06 2;534(7605):47-54. Epub 2016 May 2.

Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature17676DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910866PMC
June 2016

Molecular profiles to biology and pathways: a systems biology approach.

Chin J Cancer 2016 Jun 16;35(1):53. Epub 2016 Jun 16.

Translational Cancer Research Unit, Center for Oncological Research, Faculty of Medicine and Health Sciences, University of Antwerp, Oosterveldlaan 24, Wilrijk, 2610, Antwerp, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40880-016-0112-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910225PMC
June 2016

Increased Angiogenesis and Lymphangiogenesis in Metastatic Sentinel Lymph Nodes Is Associated With Nonsentinel Lymph Node Involvement and Distant Metastasis in Patients With Melanoma.

Am J Dermatopathol 2016 May;38(5):338-46

*Department of Dermatology, University Hospital "Clínico Lozano Blesa", Zaragoza, Spain; †Translational Cancer Research Unit Antwerp, Oncology Center, General Hospital Sint-Augustinus, Wilrijk, Belgium; ‡Department of Pathology, University Hospital "Miguel Servet", Zaragoza, Spain; §Department of Medicine, Psychiatry, and Dermatology, School of Medicine, University of Zaragoza, Zaragoza, Spain; and ¶Department of Oncology, KU of Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000000488DOI Listing
May 2016

Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.

Arch Pathol Lab Med 2016 Jan;140(1):66-74

From the Transformative Pathology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada (Dr Bartlett); Biomarker and Companion Diagnostic Group, Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom (Dr Bartlett and Ms Piper); Research and Development (Dr Christiansen) and Medical Affairs (Dr Gustavson), Genoptix, Inc, Carlsbad, California; the Department of Pathology, Yale University School of Medicine, New Haven, Connecticut (Dr Rimm); the Departments of Surgery (Dr van de Velde) and Medical Statistics and Bioinformatics (Dr Putter), Leiden University Medical Center, Leiden, The Netherlands; the Department of Gynecological Oncology, University Medical Center Freiburg, Freiburg, Germany (Dr Hasenburg); the Department of Obstetrics and Gynecology, Elblandklinikum, Riesa, Germany (Dr Kieback); the Department of Surgery, Athens University Medical School, Athens, Greece (Dr Markopoulos); Oncology Center, Sint-Augustinus, Wilrijk-Antwerp, Belgium (Dr Dirix); the Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands (Dr Seynaeve); and Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom (Dr Rea). Dr Christiansen is now with Diagnostic Development at Ignyta, Inc, San Diego, California. Dr Gustavson is now with Diagnostics Department at MetaStat, Inc, Boston, Massachusetts. Dr Kieback is now with the Department of Obstetrics and Gynecology at Klinikum Vest Medical Center, Marl, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2014-0599-OADOI Listing
January 2016

Peritumoral D2-40 Chalkley score independently predicts metastases and survival in patients with cutaneous malignant melanoma.

J Cutan Pathol 2015 Oct 11;42(10):699-711. Epub 2015 Sep 11.

Translational Cancer Research Unit Antwerp, Oncology Centre, General Hospital Sint-Augustinus, Wilrijk, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.12571DOI Listing
October 2015

Melanomas arising on skin with chronic sun-induced damage exhibit low degree of angiogenesis and lymphangiogenesis.

Am J Dermatopathol 2015 Jun;37(6):451-4

*Department of Dermatology, University Hospital "Clínico Lozano Blesa," Zaragoza, Spain; †Department of Pathology, University Hospital "Miguel Servet," Zaragoza, Spain; ‡Translational Cancer Research Unit Antwerp, Oncology Center, General Hospital Sint-Augustinus, Wilrijk, Belgium; §Department of Medicine, Psychiatry, and Dermatology, School of Medicine, University of Zaragoza, Zaragoza, Spain; and ¶Department of Oncology, KU Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/amjdermatopathology/2015/06000/
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/DAD.0000000000000265DOI Listing
June 2015

Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.

Expert Opin Biol Ther 2015 May;15(5):749-60

Sint-Augustinus Cancer Center, Department of Medical Oncology , Sint-Augustinus, Oosterveldlaan 24, 2610 Wilrijk-Antwerp , Belgium +003234433737 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2015.1036026DOI Listing
May 2015

Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.

J Clin Oncol 2015 Apr 23;33(10):1136-42. Epub 2015 Feb 23.

Ian E. Krop, Dana-Farber Cancer Institute, Boston, MA; Thomas M. Suter, Bern University Hospital, Bern, Switzerland; Chau T. Dang, Memorial Sloan Kettering Cancer Center, New York; Marc L. Citron, Hofstra North Shore-Long Island Jewish School of Medicine, New Hyde Park, NY; Luc Dirix, Sint-Augustinus Hospital, Antwerp, Belgium; Gilles Romieu, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier; Mario Campone, Institut de Cancérologie de l'Ouest/René Gauducheau, Nantes Saint-Herblain, France; Claudio Zamagni, Policlinico Sant'Orsola-Malpighi Hospital, Bologna; Luca Gianni, San Raffaele Hospital, Milan, Italy; and Na Xu and Melanie Smitt, Genentech, South San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.7782DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657012PMC
April 2015

Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer.

Cancer Lett 2015 Jan 4;356(2 Pt B):872-9. Epub 2014 Nov 4.

Translational Cancer Research Unit, Oncology Center GZA Hospitals Sint-Augustinus, Oosterveldlaan 24, Antwerp 2610, Belgium; Department of Oncology, University of Antwerp, Universiteitsplein 1, Antwerp 2610, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2014.10.039DOI Listing
January 2015

Expression profiling of migrated and invaded breast cancer cells predicts early metastatic relapse and reveals Krüppel-like factor 9 as a potential suppressor of invasive growth in breast cancer.

Oncoscience 2014 18;1(1):69-81. Epub 2013 Jan 18.

Center for Oncological Research (CORE), University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium ; Laboratory of Pathology, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem (Antwerp), Belgium.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295756PMC
http://dx.doi.org/10.18632/oncoscience.10DOI Listing
January 2015

Genomic profiling of inflammatory breast cancer: a review.

Breast 2014 Oct 4;23(5):538-45. Epub 2014 Jul 4.

Translational Cancer Research Unit, GZA Hospitals Sint-Augustinus, Wilrijk, Belgium; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; Department of Oncology, KU Leuven, Leuven, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2014.06.008DOI Listing
October 2014

Bevacizumab beyond progression in breast cancer.

Lancet Oncol 2014 Oct 28;15(11):1190-1. Epub 2014 Sep 28.

The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)70454-1DOI Listing
October 2014

Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.

Clin Cancer Res 2014 Apr 27;20(7):1935-45. Epub 2014 Jan 27.

Authors' Affiliations: Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Catalan Institute of Oncology, Barcelona, Spain; Sarah Cannon Research Institute, Nashville, Tennessee; Novartis Pharmaceuticals, East Hanover, NJ; Novartis Pharmaceuticals, Florham Park, New Jersy; C.H.U. Sart-Tilman, Liege; Oncologisch Centrum AZ-St. Augustinus Oncology, Antwerp, Belgium; Novartis Pharma AG, Basel, Switzerland; Novartis Oncology, Paris, France; Memorial Sloan-Kettering Cancer Centre, New York, New York; Highlands Oncology Group, Fayetteville, Arkansas; and Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1070DOI Listing
April 2014

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.

Clin Cancer Res 2014 Apr 21;20(8):2192-204. Epub 2014 Feb 21.

Authors' Affiliations: Institut de Cancérologie Gustave Roussy, Villejuif; Centre Francois Baclesse, CHU Côte de Nacre, Caen; Centre Léon Bérard Lyon, Lyon, France; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona; 12 de Octubre University Hospital, Madrid, Spain; Fox Chase Cancer Center, Philadelphia; Janssen Research & Development, Spring House, Pennsylvania; formerly University of Texas, MD Anderson Cancer Center, Houston, Texas; currently UC San Diego Moores Cancer Center, San Diego, California; Erasme University Hospital; Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels; AZ Sint-Augustinus, Antwerp; Janssen Research & Development, Beerse, Belgium; Southampton University Hospitals NHS Trust, Southampton; Western General Hospital, Edinburgh; University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; and Janssen Research & Development, Leiden, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2200DOI Listing
April 2014

Discovery and exploitation of novel targets by approved drugs.

Authors:
Luc Dirix

J Clin Oncol 2014 Mar 3;32(8):720-1. Epub 2014 Feb 3.

Sint-Augustinus Cancer Center, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.7118DOI Listing
March 2014

Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.

J Natl Cancer Inst 2014 Feb 7;106(2):djt376. Epub 2014 Jan 7.

Affiliations of authors: Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands (NQL, MPL, MS, RBHB, TDM, AMS, JWMM, JAF, AU); Department of Neurology (CS, TML) and Postgraduate School of Molecular Medicine (NQL, RBHB, TDM, AMS, JWMM, JAF, AU), Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Radiation Oncology (PNS) and Department of Laboratory Medicine (FCGJS), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden (BKL); Department of Oncology/Pathology, Karolinska Institute, Stockholm, Sweden (BKL); Clinical Experimental Oncology Laboratory, National Cancer Centre Giovanni Paolo II, Bari, Italy (AM, AP); Translational Cancer Research Unit, Oncology Center, GZA Hospitals St-Augustinus, Antwerp, Belgium (LYD, SJVL); Netherlands Proteomics Centre, Utrecht, The Netherlands (NQL, AU); Cancer Genomics Centre, Utrecht, The Netherlands (MS, AMS, JWMM, JAF, AU); Center for Translational Molecular Medicine, Eindhoven, The Netherlands (RBHB, JAF, AU).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/early/2014/01/06/jnci
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/djt376
Publisher Site
http://dx.doi.org/10.1093/jnci/djt376DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952199PMC
February 2014

Histopathological evaluation of resected colorectal cancer liver metastases: what should be done?

Histopathology 2014 Jan 6;64(2):315-6. Epub 2013 Nov 6.

Translational Cancer Research Unit, GZA Hospitals, Antwerp, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12259DOI Listing
January 2014

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

J Clin Oncol 2013 Nov 30;31(32):4060-6. Epub 2013 Sep 30.

Ignace B. Vergote, University Hospital Leuven, Leuven; Christine Gennigens, Centre Hospitalier Universitaire de Liège, Liège; Luc Y. Dirix, Gasthuis Zusters Antwerpen, Antwerp, Belgium; Agustin Garcia, University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles; John Micha, Gynecologic Oncology Associates, Newport Beach; Emad N. Ibrahim, Beaver Medical Group, Redlands; Abraham C.F. Leung, Carol Zhao, and Raoudha Soufi-Mahjoubi, Nektar Therapeutics, San Francisco, CA; Charles Pippitt, Piedmont Hematology Oncology Associates, Winston Salem, NC; Johanna Bendell, Sarah Cannon Research Institute, Nashville, TN; Daniel Spitz, Palm Beach Cancer Institute, West Palm Beach, FL; Nicholas Reed, Beatson Oncology Centre, Glasgow; Graham Dark, Freeman Hospital, Newcastle upon Tyne; Chris Poole, University Hospital Coventry, Coventry; Gordon Rustin, Mount Vernon Hospital, Northwood, United Kingdom; Paula M. Fracasso and Linda Duska, University of Virginia Health System, Charlottesville, VA; and Vincent A. Armenio, Pharma Resource, Providence, RI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.1278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878105PMC
November 2013

Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer.

Cancer Res 2013 Nov;73(22):6632-41

Authors' Affiliations: Department of Medical Oncology, Erasmus University Medical Center, Cancer Institute, Rotterdam; Departments of Molecular Carcinogenesis and Molecular Pathology, Central Genomic Facility, the Netherlands Cancer Institute; Agendia NV, Amsterdam, the Netherlands; and Translational Cancer Research Unit, Laboratory of Pathology, Antwerp University/Oncology Centre, GZA Hospitals St-Augustinus, Antwerp, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-0704DOI Listing
November 2013

Modeling and characterization of inflammatory breast cancer emboli grown in vitro.

Int J Cancer 2013 May 19;132(10):2283-94. Epub 2012 Dec 19.

Laboratory for Cytoskeletal Physiology, Department of Biological Sciences, The University of Delaware, Newark, DE 19716, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ijc.27928
Publisher Site
http://dx.doi.org/10.1002/ijc.27928DOI Listing
May 2013

[Vismodegib in metastasized basal cell carcinoma].

Ned Tijdschr Geneeskd 2013 ;157(12):A6011

MUMC, afd. Dermatologie, Maastricht, the Netherlands.

View Article

Download full-text PDF

Source
May 2013

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.

Breast Cancer Res Treat 2013 May 17;139(1):39-49. Epub 2013 Apr 17.

Department of Medical Oncology, Erasmus MC Cancer Institute, Room Be424, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-013-2529-7DOI Listing
May 2013

Trastuzumab emtansine in breast cancer.

Expert Opin Biol Ther 2013 Apr;13(4):607-14

St Augustinus Hospital, Translational Cancer Research Group Antwerp, Oosterveldlaan 24, Wilrijk-Antwerp, 2610, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2013.778238DOI Listing
April 2013

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.

Breast 2012 Dec 27;21(6):716-23. Epub 2012 Sep 27.

Medical Oncology & Translational Research, Jules Bordet Institute, Boulevard de Waterloo, 125, 1000 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2012.09.002DOI Listing
December 2012

Regulation of inflammatory breast cancer cell invasion through Akt1/PKBα phosphorylation of RhoC GTPase.

Mol Cancer Res 2012 Oct 15;10(10):1306-18. Epub 2012 Aug 15.

Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA.

View Article

Download full-text PDF

Source
http://mcr.aacrjournals.org/cgi/doi/10.1158/1541-7786.MCR-12
Publisher Site
http://dx.doi.org/10.1158/1541-7786.MCR-12-0173DOI Listing
October 2012

Vismodegib: a promising drug in the treatment of basal cell carcinomas.

Future Oncol 2012 Aug;8(8):915-28

Sint-Augustinus Hospital, Oosterveldlaan 24, Antwerp, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.12.82DOI Listing
August 2012